Skip to main content

Featured

CUSMA Review 2026: What Happens on July 1 — and What It Means for Your Wallet

The trade deal that governs nearly $1.3 trillion in Canada-U.S. commerce is up for review in less than a week. Here's what's at stake for Canadian families — and how to protect your budget whatever happens next. By MoneySavings.ca Staff  |   June 25, 2026 Canada Day is almost here — and this year, July 1 carries a lot more weight than fireworks and barbecues. On that same date, Canada, the United States, and Mexico are required to sit down for the first mandatory review of the Canada–United States–Mexico Agreement , known in Canada as CUSMA (and in the U.S. as the USMCA). The outcome of these talks will help shape the price of your groceries, your next car payment, Canadian jobs, and the overall cost of living for years to come. If you've heard the buzz but aren't sure what it all means for your household budget, you're in the right place. Here's your plain-language breakdown. What Is CUSMA — and Why Should You Care? CUSMA replaced the old NAFTA deal in 2020 an...
Post a Comment
Read more

article

Labels

Controversial Turkish Import Endangers Newborns in Alberta, Documents Reveal

 

Recent documents have raised alarming concerns over Alberta’s emergency importation of children’s pain medication from Turkey. Produced by Atabay Pharmaceuticals and sold under the brand name Parol Suspension, the drug is marketed at a concentration of 24 mg/ml—significantly lower than the 32 mg/ml concentration found in the standard, Canadian-authorized formulation.

Health experts and opposition critics warn that this altered concentration poses a twofold risk. First, the discrepancy could lead to dosing errors if parents and caregivers, accustomed to the standard formulation, misjudge the correct volume needed. Second, there are fears that the lower concentration may lead to the clogging of hospital feeding tubes—a critical concern for vulnerable newborns.

Alberta Blue Cross has informed pharmacists that Parol must be dispensed with enhanced caution, requiring additional education on its proper use. Critics argue that the rushed procurement—amounting to approximately $80 million—exemplifies a misstep in prioritizing political expedience over stringent safety protocols. With traditional supplies of children’s pain medications already in short supply, many worry that this controversial alternative might jeopardize the health of Alberta’s youngest patients.

Further review and tighter regulatory oversight are now being called for, as stakeholders demand that the province safeguard the well-being of newborns and ensure that emergency measures do not compromise pediatric care.

Labels:

Comments

Post a Comment